LRP1B: A Giant Lost in Cancer Translation

Pharmaceuticals

Isabel J. Dionísio de Sousa¹  Catarina Príncipe²  Paula Soares²  Hugo Prazeres²  Raquel T. Lima² 

[1] Department of Oncology, Centro HospitalarUniversitário de São João, 4200-450 Porto, Portugal;i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal;

关键词: LRP1B;    endocytic receptor;    cancer;    tumor suppressor;    biomarker;    prognosis;   

DOI  :  10.3390/ph14090836

来源: DOAJ

【 摘 要 】

Low-density lipoprotein receptor-related protein 1B (LRP1B) is a giant member of the LDLR protein family, which includes several structurally homologous cell surface receptors with a wide range of biological functions from cargo transport to cell signaling. LRP1B is among the most altered genes in human cancer overall. Found frequently inactivated by several genetic and epigenetic mechanisms, it has mostly been regarded as a putative tumor suppressor. Still, limitations in LRP1B studies exist, in particular associated with its huge size. Therefore, LRP1B expression and function in cancer remains to be fully unveiled. This review addresses the current understanding of LRP1B and the studies that shed a light on the LRP1B structure and ligands. It goes further in presenting increasing knowledge brought by technical and methodological advances that allow to better manipulate LRP1B expression in cells and to more thoroughly explore its expression and mutation status. New evidence is pushing towards the increased relevance of LRP1B in cancer as a potential target or translational prognosis and response to therapy biomarker.

【 授权许可】

Unknown